Introduction
============

In the last few years, accumulating evidence has indicated that numerous long noncoding RNAs (lncRNAs) are abnormally expressed in gastric cancer (GC) and are associated with the survival of GC patients.[@b1-ott-11-4877]--[@b113-ott-11-4877] GC is the fourth most diagnosed tumor type and the third most common origin of tumor-related death all over the world.[@b114-ott-11-4877],[@b115-ott-11-4877] Although the incidence and mortality of GC are declining, \>24,590 individuals are diagnosed with GC per year, of which 10,720 die from GC in the USA.[@b116-ott-11-4877] Although diagnosis and treatment strategies have been improved, the number of surviving cases remains low, since diagnosis often occurs in the late stages.[@b116-ott-11-4877],[@b117-ott-11-4877] Thus, the molecular characteristics about the carcinogenesis of GC and the recognition of new biomarkers for GC are urgently needed.

lncRNA is a new type of noncoding RNA that has a length of \>200 nucleotides (nt) and lacks important open reading frameworks and can be divided into five main categories (sense, antisense, bidirectional, intronic and intergenic).[@b118-ott-11-4877] Abundant evidence has demonstrated that lncRNAs play significant regulatory roles in tumor biology via various mechanisms affecting transcriptional and posttranscriptional levels.[@b118-ott-11-4877]--[@b120-ott-11-4877] Currently, for both cell behavior and clinicopathological factors, significant advances with respect to lncRNA effects on GC have been discovered.[@b121-ott-11-4877]

On account of the obvious expression differences between normal and malignant tissues as well as causal roles of lncRNAs in cancer development, lncRNAs are now attracting increasing attention, which has led to numerous investigations of the correlation between lncRNA states and clinical results in GC. Nevertheless, most of these studies were performed with small samples, and there were inconsistently observed connections. Consequently, we conducted a meta-analysis to determine the accurate role of lncRNAs in the prognosis of GC patients, which possibly supplied us with new insights into the clinical value of combined detection in forecasting prognostic results and determining promising biomarkers in GC treatment strategies.

Methods
=======

Literature search strategy
--------------------------

We basically performed a systematic selection of papers published in English from four databases (PubMed, Web of Science, Embase and Cochrane Database of Systematic Reviews). A comprehensive search was conducted using the subject term: lncRNA and gastric cancer. Two authors (Song Gao and Zhi-Ying Zhao) checked the titles and abstracts of the retrieved papers, and Yue Zhang reevaluated uncertain data. [Figure 1](#f1-ott-11-4877){ref-type="fig"} shows the flow diagram of the literature search and selection.

Inclusion criteria
------------------

We set up inclusion criteria for qualified papers, which were analyzed using our full-text assessment: 1) articles concerning the pertinence between lncRNA level in cancer tissues and prognosis of GC patients; 2) the survival results were estimated using overall survival (OS) and 3) full-text papers published in English.

Exclusion criteria
------------------

Articles that did not meet the abovementioned inclusion criteria, reviews, letters and laboratory studies without raw data were excluded. Articles of non-dichotomous lncRNA expression levels and frequency of studies evaluating prognostic value of lncRNAs equal to 1 were also excluded. If more than one paper had been published on the identical study cohort, only the most well-rounded investigation was selected for this research. In addition, if both of the univariate and multivariate outcomes were covered, only the latter were chosen, since they were adjusted for confounding factors.

Research frequency
------------------

[Table 1](#t1-ott-11-4877){ref-type="table"} gives the frequency of investigations reporting prognosis of GC patients, which included the lncRNA name, frequency of researched lncRNA and reference.

Data extraction
---------------

The survival data were recovered from qualified articles independently by two authors (Song Gao and Zhi-Ying Zhao). Data extracted from them are as follows: researched lncRNA, first author's name, paper publication year, reference, patient's nationality, study design, histological type, patient number, neoplasm staging, cutoff value, detected method, follow-up period, survival analysis type, HRs and 95% CIs. The detailed data are shown in [Table 2](#t2-ott-11-4877){ref-type="table"}. If HR and 95% CI were not directly shown in the paper, data from survival curve were extracted. Disagreements were discussed with the third investigator (Yue Zhang).

Statistical analysis
--------------------

Stata version 13.0 (StataCorp LP, College Station, TX, USA) was used for the whole meta-analysis. HR and 95% CI from GC patients were calculated on the basis of survival curve and patient number using Engauge Digitizer version 4.1 and Tierney's method.[@b122-ott-11-4877] The random-effect model was used in the whole article because different histological type (frozen, formalin-fixed paraffin-embedded or undefined) from GC patients at different neoplasm staging, cutoff value and lncRNA detected method was used in the single study. The HR was considered significant if its *P*-value was \<0.05 and 95% CI did not contain the value 1. Furthermore, the lncRNA was considered as a strong biomarker of prognosis, if its HR was \>2. The Begg's funnel plot was used to estimate publication bias, and a two-tailed *P*-value \<0.05 was considered as significant. The sensitivity analysis was performed to examine how sensitive the merged HR was if the single study was removed, and if the point of evaluation was outside the 95% CI after it was removed from the whole analysis, a single research was considered as excessive influence.

Results
=======

Meta-analysis
-------------

[Table 3](#t3-ott-11-4877){ref-type="table"} gives the basic information of the merged meta-analysis for researched lncRNAs.

### AFAP1 antisense RNA 1 (AFAP1-AS1), CDKN2B antisense RNA 1 (ANRIL), cancer susceptibility 15 (CASC15), colon cancer-associated transcript 2 (CCAT2), gastric adenocarcinoma associated, positive CD44 regulator, long intergenic noncoding RNA (GAPLINC) and H19, imprinted maternally expressed transcript (H19) demonstrated significantly prognostic value

Two articles[@b3-ott-11-4877],[@b4-ott-11-4877] reported the relationship between high AFAP1-AS1 expression and OS, indicating that GC patients with its high expression had significantly worse OS than those with its low expression (HR=2.47, 95% CI=1.41--4.30, *P*\<0.01).

Two researches[@b9-ott-11-4877],[@b10-ott-11-4877] covered the connections between high ANRIL expression and OS, suggesting that GC patients with its high expression had significantly poorer OS than those with its low expression (HR=1.68, 95% CI=1.16--2.43, *P*\<0.01).

Two investigations[@b18-ott-11-4877],[@b19-ott-11-4877] analyzed the associations between high CASC15 expression and OS, showing that GC patients with its high expression had significantly shorter OS than those with its low expression (HR=1.99, 95% CI=1.21--3.28, *P*\<0.01).

Two studies[@b21-ott-11-4877],[@b22-ott-11-4877] focused on the correlation between high CCAT2 expression and OS, manifesting that GC patients with its high expression had significantly worse OS than those with its low expression (HR=2.17, 95% CI=1.53--3.09, *P*\<0.01).

Two papers[@b32-ott-11-4877],[@b33-ott-11-4877] paid attention to the pertinence between high GAPLINC expression and OS, demonstrating that GC patients with its high expression had significantly poorer OS than those with its low expression (HR=1.49, 95% CI=1.18--1.89, *P*\<0.01).

Four literature[@b29-ott-11-4877],[@b36-ott-11-4877]--[@b38-ott-11-4877] described the relativity between high H19 expression and OS, proving that GC patients with its high expression had significantly shorter OS than those with its low expression (HR=1.51, 95% CI=1.05--2.17, *P*=0.03; [Figure 2](#f2-ott-11-4877){ref-type="fig"}).

### HOX transcript antisense RNA (HOTAIR) demonstrated significantly prognostic value

Nine essays[@b41-ott-11-4877]--[@b49-ott-11-4877] discussed the relation between high HOTAIR expression and OS, illuminating that GC patients with its high expression had significantly worse OS than those with its low expression (HR=1.93, 95% CI=1.53--2.43, *P*\<0.01; [Figure 3](#f3-ott-11-4877){ref-type="fig"}).

### Publication bias

The Begg's funnel plot was used to estimate publication bias, and its *P*-value was 0.20, so there was no significant publication bias in the pooled analysis of OS about high HOTAIR expression ([Figure 4](#f4-ott-11-4877){ref-type="fig"}).

### Sensitivity analysis

The sensitivity analysis was performed to examine how sensitive the merged HR was if the single study was removed. After this process, no individual study significantly affected the combined HR with 95% CI ([Figure 5](#f5-ott-11-4877){ref-type="fig"}).

### HOXA distal transcript antisense RNA (HOTTIP), long intergenic non-protein coding RNA 673 (LINC00673), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), maternally expressed 3 (MEG3), promoter of CDKN1A antisense DNA damage activated RNA (PANDAR) and Pvt1 oncogene (PVT1) demonstrated significantly prognostic value

The details are shown in [Table 3](#t3-ott-11-4877){ref-type="table"} and [Figure 6](#f6-ott-11-4877){ref-type="fig"}.

### SOX2 overlapping transcript (Sox2ot), urothelial cancer-associated 1 (UCA1), X inactive specific transcript (XIST), ZEB1 antisense RNA 1 (ZEB1-AS1) and ZNFX1 antisense RNA 1 (ZFAS1) demonstrated significantly prognostic value

The details are shown in [Table 3](#t3-ott-11-4877){ref-type="table"} and [Figure 7](#f7-ott-11-4877){ref-type="fig"}.

Discussion
==========

Current situation
-----------------

So far, the clinical treatment of GC remains limited. In the past score years, there has been little progress in both traditional and new treatment methods. Therefore, novel biomarkers that can improve the prognosis of GC patients are in need. Recently, there is an increasing evidence that lncRNAs can hinder the growth and metastasis of cancer. For example, Xu et al[@b123-ott-11-4877] reported that upregulating long stress-induced noncoding 5 (LSINCT5) significantly promoted the growth of the GC cell, while downregulating LSINCT5 suppressed its growth. Dan et al[@b124-ott-11-4877] conducted the cancer model experiments using mice, proving that MEG3 overexpression could suppress GC growth and metastasis in vivo by suppressing miR-21 expression. More importantly, several abnormally expressed lncRNAs have been discovered to touch upon the development of GC and perhaps possess prognostic potency in this illness. In view of the above consequences, we conducted this meta-analysis about the prognostic value of lncRNAs in GC.

Research finding
----------------

In the present research, a total of 51 articles reporting 19 lncRNAs, which were latent prognostic biomarkers and 6,095 GC patients were included, among which 18 lncRNAs (except SPRY4 intronic transcript 1 \[SPRY4-IT1\]) manifested a significantly prognostic value. Meanwhile, strong heterogeneity was only shown in two (H19 and SPRY4-IT1) analyses about lncRNAs, during which there was no significant associations between SPRY4-IT1 expression and OS. Further analysis suggested that AFAP1-AS1, CCAT2, LINC00673, PANDAR, PVT1, Sox2ot, ZEB1-AS1 and ZFAS1 were strong candidates in predicting prognosis of GC patients.

Molecular mechanisms
--------------------

[Figure 8](#f8-ott-11-4877){ref-type="fig"} shows the summary of lncRNAs with aberrant expression, potential targets and pathways included in this study. It is noteworthy that there existed inconsistent outcomes about expression of HOTTIP and SPRY4-IT1 compared with normal controls, so these two lncRNAs were not shown to be up or down expressed. Unexpected results were findings that CDKN1A was target of both CASC15 and PANDAR and KLF2 was target of both LINC00673 and ZFAS1. In addition, cell proliferation was the most related cell function of these lncRNAs.

Merits
------

The current study had several merits: 1) nearly all articles appraising the associations between OS of GC patients and lncRNA expression were searched and are clearly shown in [Table 1](#t1-ott-11-4877){ref-type="table"}; 2) most of our meta-analyses revealed no or low heterogeneity (*I*^2^≤50.0%), indicating relatively consistent results of the meta-analyses and 3) all the included studies had a relatively large sample size (≥30), decreasing the error of low sample size to some degree.

Limitations
-----------

However, the limitations of this work could not be ignored: 1) only English papers were included in the present research, which may exclude potentially relevant articles; 2) most of the patients were from China, which cannot adequately represent the prognosis of global patients; 3) only the meta-analysis of HOTAIR was composed of nine articles,[@b41-ott-11-4877]--[@b49-ott-11-4877] and other merged analyses about lncRNAs were from relatively small article number (two to four) and 4) the papers omitted due to no mention of OS may provide a lot of information on which lncRNAs hold promise for a prognostic value.

Inspirations
------------

This study left several inspirations for us: 1) lncRNAs were arranged in an alphabetical order as shown in [Table 1](#t1-ott-11-4877){ref-type="table"}, via which the recently research frequency could be distinctly seen by clinical workers and scientific researchers; 2) the detailed outcomes of OS from the pooled analyses are shown in [Table 3](#t3-ott-11-4877){ref-type="table"}, through which combined detection of lncRNAs might better predict the survival time of GC patients and 3) for the molecular mechanisms of the included lncRNAs, their connections are shown in [Figure 8](#f8-ott-11-4877){ref-type="fig"}, which might play enlightening roles in future basic experiments on lncRNAs in GC.

Conclusion
==========

This meta-analysis suggested that the abnormally expressed lncRNAs (AFAP1-AS1, ANRIL, CASC15, CCAT2, GAPLINC, H19, HOTAIR, HOTTIP, LINC00673, MALAT1, MEG3, PANDAR, PVT1, Sox2ot, UCA1, XIST, ZEB1-AS1 and ZFAS1) were significantly associated with the survival of GC patients, among which AFAP1-AS1, CCAT2, LINC00673, PANDAR, PVT1, Sox2ot, ZEB1-AS1 and ZFAS1 were strong candidates in predicting prognosis of GC patients.
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![Forest plot of pooled analyses of OS in association with high AFAP1-AS1, ANRIL, CASC15, CCAT2, GAPLINC and H19 expression levels.\
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![Beggs's funnel plot of publication bias for pooled analysis of OS in association with high HOTAIR expression levels.\
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![Forest plot of pooled analyses of OS in association with high HOTTIP, LINC00673, MALAT1, PANDAR, PVT1 expression levels, or low MEG3 expression levels.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** GEO, Gene Expression Omnibus; HOTTIP, HOXA distal transcript antisense RNA; LINC00673, long intergenic non-protein coding RNA 673; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed 3; OS, overall survival; PANDAR, promoter of CDKN1A antisense DNA damage activated RNA; PVT1, Pvt1 oncogene; TCGA, The Cancer Genome Atlas.](ott-11-4877Fig6){#f6-ott-11-4877}

![Forest plot of pooled analyses of OS in association with high Sox2ot, UCA1, XIST, ZEB1-AS1, ZFAS1 expression levels, or low SPRY4-IT1 expression levels.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** OS, overall survival; Sox2ot, SOX2 overlapping transcript; SPRY4-IT1, SPRY4 intronic transcript 1; UCA1, urothelial cancer associated 1; XIST, X inactive specific transcript; ZEB1-AS1, ZEB1 antisense RNA 1; ZFAS1, ZNFX1 antisense RNA 1.](ott-11-4877Fig7){#f7-ott-11-4877}

![Summary of lncRNAs with altered expression, potential targets and pathways entered in this study.\
**Abbreviations:** AFAP1-AS1, AFAP1 antisense RNA 1; ANRIL, CDKN2B antisense RNA 1; CASC15, cancer susceptibility 15; CCAT2, colon cancer associated transcript 2; EMT, epithelial--mesenchymal transition; GAPLINC, gastric adenocarcinoma associated, positive CD44 regulator, long intergenic noncoding RNA; H19, H19, imprinted maternally expressed transcript; HOTAIR, HOX transcript antisense RNA; HOTTIP, HOXA distal transcript antisense RNA; LINC00673, long intergenic non-protein coding RNA 673; lncRNA, long noncoding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed 3; PANDAR, promoter of CDKN1A antisense DNA damage activated RNA; PVT1, Pvt1 oncogene; Sox2ot, SOX2 overlapping transcript; SPRY4-IT1, SPRY4 intronic transcript 1; UCA1, urothelial cancer associated 1; XIST, X inactive specific transcript; ZEB1-AS1, ZEB1 antisense RNA 1; ZFAS1, ZNFX1 antisense RNA 1.](ott-11-4877Fig8){#f8-ott-11-4877}

###### 

Research frequency of lncRNAs in GC

  lncRNA         n   R                                        lncRNA         n   R                                                            lncRNA            n   R
  -------------- --- ---------------------------------------- -------------- --- ------------------------------------------------------------ ----------------- --- ------------------------------------------
  AC027119.1     1   [@b1-ott-11-4877]                        H19            4   [@b29-ott-11-4877], [@b36-ott-11-4877]--[@b38-ott-11-4877]   NEAT1             1   [@b83-ott-11-4877]
  AC138128.1     1   [@b2-ott-11-4877]                        HAGLROS        1   [@b39-ott-11-4877]                                           NR_003573         1   [@b7-ott-11-4877]
  ADAMTS9-AS2    1   [@b1-ott-11-4877]                        HIF1A-AS2      1   [@b40-ott-11-4877]                                           OR3A4             1   [@b84-ott-11-4877]
  AFAP1-AS1      2   [@b3-ott-11-4877], [@b4-ott-11-4877]     HOTAIR         9   [@b41-ott-11-4877]--[@b59-ott-11-4877]                       OTUB1-isoform 2   1   [@b85-ott-11-4877]
  AGAP2-AS1      1   [@b5-ott-11-4877]                        HOTTIP         3   [@b50-ott-11-4877]--[@b52-ott-11-4877]                       PANDAR            2   [@b86-ott-11-4877], [@b87-ott-11-4877]
  AK023391       1   [@b6-ott-11-4877]                        HOXA-AS2       1   [@b53-ott-11-4877]                                           PCAT1             1   [@b88-ott-11-4877]
  AK093735       1   [@b7-ott-11-4877]                        HXA11-AS       1   [@b54-ott-11-4877]                                           PVT1              2   [@b89-ott-11-4877], [@b90-ott-11-4877]
  AK123072       1   [@b8-ott-11-4877]                        KRTI8P55       1   [@b55-ott-11-4877]                                           RP11-119F7.4      1   [@b91-ott-11-4877]
  ANRIL          2   [@b9-ott-11-4877], [@b10-ott-11-4877]    LET            1   [@b56-ott-11-4877]                                           RP11-120K18.2     1   [@b1-ott-11-4877]
  ATB            1   [@b11-ott-11-4877]                       LINC00052      1   [@b57-ott-11-4877]                                           RP11-389G6.3      1   [@b1-ott-11-4877]
  BANCR          1   [@b12-ott-11-4877]                       LINC00152      1   [@b58-ott-11-4877]                                           RP11-499F3.2      1   [@b1-ott-11-4877]
  BC005927       1   [@b13-ott-11-4877]                       LINC00628      1   [@b59-ott-11-4877]                                           RP11-789C1.1      1   [@b92-ott-11-4877]
  BC032469       1   [@b14-ott-11-4877]                       LINC00668      1   [@b60-ott-11-4877]                                           RPLPOP2           1   [@b29-ott-11-4877]
  BC041951       1   [@b15-ott-11-4877]                       LINC00673      2   [@b61-ott-11-4877], [@b62-ott-11-4877]                       SLC26A4           1   [@b29-ott-11-4877]
  BCAR4          1   [@b16-ott-11-4877]                       LINC00675      1   [@b63-ott-11-4877]                                           SMIM10L2A         1   [@b29-ott-11-4877]
  CASC2          1   [@b17-ott-11-4877]                       LINC00982      1   [@b64-ott-11-4877]                                           SMIM10L2B         1   [@b29-ott-11-4877]
  CASC15         2   [@b18-ott-11-4877], [@b19-ott-11-4877]   LINC01018      1   [@b65-ott-11-4877]                                           SNHG1             1   [@b93-ott-11-4877]
  CCAT1          1   [@b20-ott-11-4877]                       LINC01234      1   [@b66-ott-11-4877]                                           SNHG6             1   [@b94-ott-11-4877]
  CCAT2          2   [@b21-ott-11-4877], [@b22-ott-11-4877]   LINC01296      1   [@b67-ott-11-4877]                                           SNHG12            1   [@b95-ott-11-4877]
  CHRDL1         1   [@b23-ott-11-4877]                       LINC-ROR       1   [@b68-ott-11-4877]                                           SNORD116-4        1   [@b29-ott-11-4877]
  CTD-2147F2.1   1   [@b1-ott-11-4877]                        LINC-UBC1      1   [@b69-ott-11-4877]                                           Sox2ot            2   [@b96-ott-11-4877], [@b97-ott-11-4877]
  DANCR          1   [@b24-ott-11-4877]                       LOC100130476   1   [@b70-ott-11-4877]                                           SPRY4-IT1         2   [@b98-ott-11-4877], [@b99-ott-11-4877]
  DLX6-AS1       1   [@b1-ott-11-4877]                        LOC553137      1   [@b65-ott-11-4877]                                           TINCR             1   [@b29-ott-11-4877]
  E2F1           1   [@b25-ott-11-4877]                       MACC1          1   [@b71-ott-11-4877]                                           TTTY14            1   [@b65-ott-11-4877]
  EGOT           1   [@b26-ott-11-4877]                       MACC1-AS1      1   [@b71-ott-11-4877]                                           TUG1              1   [@b100-ott-11-4877]
  FENDRR         1   [@b27-ott-11-4877]                       MALAT1         4   [@b43-ott-11-4877], [@b72-ott-11-4877]--[@b74-ott-11-4877]   UCA1              4   [@b101-ott-11-4877]--[@b104-ott-11-4877]
  FEZF1-AS1      1   [@b28-ott-11-4877]                       MANCR          1   [@b75-ott-11-4877]                                           VPS9D1-AS1        1   [@b105-ott-11-4877]
  FOXD2-AS1      1   [@b29-ott-11-4877]                       MEG3           2   [@b76-ott-11-4877], [@b77-ott-11-4877]                       XIAP-AS1          1   [@b106-ott-11-4877]
  FRLnc1         1   [@b30-ott-11-4877]                       MIR31HG        1   [@b78-ott-11-4877]                                           XIST              2   [@b107-ott-11-4877], [@b108-ott-11-4877]
  GACAT3         1   [@b31-ott-11-4877]                       MIR4435-2HG    1   [@b65-ott-11-4877]                                           XLOC_010235       1   [@b92-ott-11-4877]
  GAPLINC        2   [@b32-ott-11-4877], [@b33-ott-11-4877]   MLK7-AS1       1   [@b79-ott-11-4877]                                           ZEB1-AS1          2   [@b109-ott-11-4877], [@b110-ott-11-4877]
  GAS5           1   [@b34-ott-11-4877]                       MLLT4-AS1      1   [@b80-ott-11-4877]                                           ZFAS1             2   [@b111-ott-11-4877], [@b112-ott-11-4877]
  GBET1          1   [@b35-ott-11-4877]                       MRUL           1   [@b81-ott-11-4877]                                           ZMAT1             1   [@b113-ott-11-4877]
  GClnc1         1   [@b15-ott-11-4877]                       MTM            1   [@b82-ott-11-4877]                                                                 

**Notes:** Highlighted lncRNAs were included in the meta-analysis. n, number of research frequency; R, reference.

**Abbreviations:** AFAP1-AS1, AFAP1 antisense RNA 1; ANRIL, CDKN2B antisense RNA 1; CASC15, cancer susceptibility 15; CCAT2, colon cancer associated transcript 2; GAPLINC, gastric adenocarcinoma associated, positive CD44 regulator, long intergenic noncoding RNA; GC, gastric cancer; H19, H19, imprinted maternally expressed transcript; HOTAIR, HOX transcript antisense RNA; HOTTIP, HOXA distal transcript antisense RNA; LINC00673, long intergenic non-protein coding RNA 673; lncRNA, long noncoding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed 3; PANDAR, promoter of CDKN1A antisense DNA damage activated RNA; PVT1, Pvt1 oncogene; Sox2ot, SOX2 overlapping transcript; SPRY4-IT1, SPRY4 intronic transcript 1; UCA1, urothelial cancer associated 1; XIST, X inactive specific transcript; ZEB1-AS1, ZEB1 antisense RNA 1; ZFAS1, ZNFX1 antisense RNA 1.

###### 

Basic information of included articles

  lncRNA      Study                                              Country/source   Study design   Sample   Number   Stage        Cutoff   Method       Follow-up (months)   OS             HR (L/H)     HR (H/L)   95% CI
  ----------- -------------------------------------------------- ---------------- -------------- -------- -------- ------------ -------- ------------ -------------------- -------------- ------------ ---------- -------------
  AFAP1-AS1   Feng et al[@b3-ott-11-4877]                        China            R              Frozen   91       I--IV        None     qRT-PCR      66                   Multivariate                3.32       1.55--5.90
  AFAP1-AS1   Qiao et al[@b4-ott-11-4877]                        China            R              Frozen   87       I--IV        Median   qRT-PCR      60                   Univariate                  1.88       1.01--3.52
  ANRIL       Zhang et al[@b9-ott-11-4877]                       China            R              Tissue   120      I--IV        3        qRT-PCR      60                   Multivariate                1.74       1.04--2.93
  ANRIL       Deng et al[@b10-ott-11-4877]                       China            R              Tissue   100      I--IV        None     qRT-PCR      .60                  Univariate                  1.61       0.95--2.74
  CASC15      Yao et al[@b18-ott-11-4877]                        China            R              Tissue   60       I--IV        None     qRT-PCR      60                   Univariate                  2.33       1.15--4.72
  CASC15      Wu et al[@b19-ott-11-4877]                         China            R              Tissue   88       I--IV        Mean     qRT-PCR      60                   Univariate                  1.70       0.84--3.47
  CCAT2       Wang et al[@b21-ott-11-4877]                       China            R              Frozen   85       I--IV        Mean     qRT-PCR      60                   Multivariate                2.41       1.19--5.42
  CCAT2       Wang et al[@b22-ott-11-4877]                       China            R              Frozen   108      I--IV        Median   qRT-PCR      66                   Multivariate                2.11       1.44--3.20
  GAPLINC     Hu et al[@b32-ott-11-4877]                         China            R              Tissue   90       I--IV        Median   RT-qPCR      .60                  Multivariate                1.48       1.16--1.89
  GAPLINC     Liu et al[@b33-ott-11-4877]                        China            R              Frozen   33       None         2.03     qRT-PCR      60                   Univariate                  1.77       0.57--5.52
  H19         Li et al[@b36-ott-11-4877]                         China            R              Frozen   74       I--IV        Mean     qRT-PCR      53                   Univariate                  2.26       0.58--8.86
  H19         Zhang et al[@b37-ott-11-4877]                      China            R              Frozen   80       I--IV        Mean     qRT-PCR      60                   Multivariate                1.14       1.01--1.29
  H19         Chen et al[@b38-ott-11-4877]                       China            R              Tissue   128      I--IV        4.615    qRT-PCR      48                   Multivariate                1.96       0.97--3.97
  H19         Li et al[@b29-ott-11-4877]                         TCGA             R              Tissue   361      I--IV        None     Downloaded   .50                  Univariate                  1.79       1.26--2.53
  HOTAIR      Endo et al[@b41-ott-11-4877]                       China I          R              Frozen   36       I--IV        1.0      qRT-PCR      .60                  Univariate                  0.95       0.21--4.31
                                                                 China II                                 32                                                                                           5.12       0.96--27.18
  HOTAIR      Xu et al[@b42-ott-11-4877]                         China            R              Frozen   83       I--IV        None     RT-qPCR      .72                  Multivariate                2.13       1.00--4.50
  HOTAIR      Okugawa et al[@b43-ott-11-4877]                    Japan            R              Frozen   150      III--IV      0.239    RT-qPCR      60                   Multivariate                1.77       1.06--2.95
  HOTAIR      Liu et al[@b44-ott-11-4877]                        China            R              Both     78       II--IV       Median   qRT-PCR      \>40                 Multivariate                4.08       2.07--8.04
  HOTAIR      Zhang et al[@b45-ott-11-4877]                      China            R              Both     50       II--IV       Median   qRT-PCR      \>45                 Univariate                  2.86       1.16--7.03
  HOTAIR      Zhao et al[@b46-ott-11-4877]                       China            R              Tissue   168      III--IV      Median   qRT-PCR      \>60                 Multivariate                1.47       1.04--2.06
  HOTAIR      Chen et al[@b47-ott-11-4877]                       China            R              Frozen   65       I--IV        2.35     qRT-PCR      \>60                 Multivariate                2.00       1.06--3.77
  HOTAIR      Feng and Huang[@b48-ott-11-4877]                   China            R              Tissue   32       None         None     qRT-PCR      \>120                Univariate                  1.52       0.45--5.14
  HOTAIR      Li et al[@b49-ott-11-4877]                         China            R              FFPE     100      I--IV        Mean     qRT-PCR      90                   Univariate                  1.83       0.82--4.05
  HOTTIP      Ye et al[@b50-ott-11-4877]                         China            R              Frozen   98       I--III       Median   qRT-PCR      60                   Univariate                  2.06       0.97--4.38
  HOTTIP      Yang et al[@b51-ott-11-4877]                       China            R              Frozen   94       I--III       Median   RT-qPCR      54                   Univariate                  1.03       0.52--2.05
  HOTTIP      Zhao et al[@b52-ott-11-4877]                       GEO              R              Tissue   348      I--IV        None     Downloaded   \>150                Univariate                  1.63       1.19--2.23
  LINC00673   Ba et al[@b61-ott-11-4877]                         China            R              Frozen   79       I--IV        Median   qRT-PCR      66                   Multivariate                2.56       1.01--4.54
  LINC00673   Huang et al[@b62-ott-11-4877]                      China            R              Tissue   73       I--IV        2        qRT-PCR      \>40                 Multivariate                2.38       1.12--5.06
  MALAT1      Qi et al[@b72-ott-11-4877]                         TCGA             R              Tissue   118      III--IV      None     RT-qPCR      \>50                 Univariate                  1.98       1.38--2.83
  MALAT1      Li et al[@b73-ott-11-4877]                         China            R              Tissue   78       I--IV        None     qRT-PCR      \>60                 Univariate                  2.52       1.35--4.68
  MALAT1      Li et al[@b74-ott-11-4877]                         China            R              FFPE     150      I--IV        None     RT-qPCR      \>150                Univariate                  1.38       1.03--1.85
  MALAT1      Okugawa et al[@b43-ott-11-4877]                    Japan            R              Frozen   150      III--IV      0.985    RT-qPCR      60                   Univariate                  1.54       0.92--2.58
  MEG3        Sun et al[@b76-ott-11-4877]                        China            R              Frozen   72       II--IV       Median   RT-qPCR      48                   Univariate     1.93                    0.99--3.75
  MEG3        Guo et al[@b77-ott-11-4877]                        China            R              Frozen   134      I--IV        None     qRT-PCR      \>60                 Univariate     2.00                    0.88--4.54
  PANDAR      Ma et al[@b86-ott-11-4877]                         China            R              Tissue   100      I--IV        None     qRT-PCR      36                   Multivariate                3.68       1.13--12.06
  PANDAR      Liu et al[@b87-ott-11-4877]                        China            R              Tissue   146      I--IV        Mean     qRT-PCR      84                   Multivariate                3.10       2.70--3.54
  PVT1        Kong et al[@b89-ott-11-4877]                       China            R              Tissue   80       I--IV        Median   qRT-PCR      36                   Multivariate                2.09       1.07--4.10
  PVT1        Yuan et al[@b90-ott-11-4877]                       China            R              Tissue   111      I--IV        Median   qRT-PCR      48                   Multivariate                2.28       1.05--4.93
  Sox2ot      Zhang et al[@b96-ott-11-4877]                      China            R              Frozen   132      I--IV        Median   qRT-PCR      \>84                 Multivariate                2.05       1.28--3.30
  Sox2ot      Zou et al[@b97-ott-11-4877]                        China            R              Tissue   155      None         Median   qRT-PCR      \>60                 Univariate                  3.24       1.24--6.43
  SPRY4-IT1   Peng et al[@b98-ott-11-4877]                       China            R              Frozen   175      I--IV        Median   qRT-PCR      60                   Multivariate   0.82                    0.31--1.57
  SPRY4-IT1   Xie et al[@b99-ott-11-4877]                        China            R              Frozen   61       I--IV        Median   qRT-PCR      36                   Univariate     2.49                    1.08--5.75
  UCA1        Zheng et al[@b101-ott-11-4877]                     China            R              Frozen   112      I--IV        Median   RT-qPCR      60                   Multivariate                2.35       1.22--4.52
  UCA1        Nasrollahzadeh-Khakiani et al[@b102-ott-11-4877]   TCGA             R              Tissue   188      I--IV        Median   Downloaded   \>116                Univariate                  1.11       0.72--1.73
  UCA1        Zuo et al[@b103-ott-11-4877]                       China            R              Frozen   37       I--IV        Median   qRT-PCR      36                   Multivariate                2.92       1.07--7.96
  UCA1        Gu et al[@b104-ott-11-4877]                        China            R              Frozen   62       I--IV        None     qRT-PCR      60                   Univariate                  1.80       0.95--3.38
  XIST        Chen et al[@b107-ott-11-4877]                      China            R              Frozen   106      I--IV        Median   qRT-PCR      \>90                 Multivariate                1.72       1.32--2.26
  XIST        Ma et al[@b108-ott-11-4877]                        China            R              FFPE     98       I--IV        None     qRT-PCR      54                   Univariate                  2.49       1.40--4.42
  ZEB1-AS1    Li et al[@b109-ott-11-4877]                        China            R              Tissue   124      I--IV        Median   qRT-PCR      72                   Multivariate                2.36       1.41--3.96
  ZEB1-AS1    Zhang et al[@b110-ott-11-4877]                     China            R              Frozen   76       I--IV        Median   qRT-PCR      90                   Univariate                  2.72       1.27--5.84
  KM          R                                                  Tissue           631            I--IV    None     Downloaded   \>150    Univariate                        1.95           1.52--2.49              
  ZFAS1       Zhang et al[@b111-ott-11-4877]                     China            R              Frozen   104      I--IV        Median   qRT-PCR      60                   Multivariate                2.57       1.25--6.84
  ZFAS1       Nie et al[@b112-ott-11-4877]                       China            R              Tissue   54       I--IV        Median   qRT-PCR      36                   Univariate                  2.43       0.96--6.17

**Abbreviations:** AFAP1-AS1, AFAP1 antisense RNA 1; ANRIL, CDKN2B antisense RNA 1; Both, frozen and formalin-fixed paraffin-embedded tissues; CASC15, cancer susceptibility 15; CCAT2, colon cancer associated transcript 2; FFPE, formalin-fixed paraffin-embedded; GAPLINC, gastric adenocarcinoma associated, positive CD44 regulator, long intergenic noncoding RNA; GEO, Gene Expression Omnibus; H19, H19, imprinted maternally expressed transcript; HOTAIR, HOX transcript antisense RNA; HOTTIP, HOXA distal transcript antisense RNA; HR (H/L), hazard ratios of high expression versus low expression of lncRNAs; HR (L/H), hazard ratios of low expression versus high expression of lncRNAs; KM, Kaplan--Meier plotter; LINC00673, long intergenic non-protein coding RNA 673; lncRNA, long noncoding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed 3; OS, overall survival; PANDAR, promoter of CDKN1A antisense DNA damage activated RNA; PVT1, Pvt1 oncogene; qRT-PCR, quantitative real-time polymerase chain reaction; R, retrospective; RT-qPCR, reverse transcription quantitative real-time polymerase chain reaction; Sox2ot, SOX2 overlapping transcript; SPRY4-IT1, SPRY4 intronic transcript 1; TCGA, The Cancer Genome Atlas; UCA1, urothelial cancer associated 1; XIST, X inactive specific transcript; ZEB1-AS1, ZEB1 antisense RNA 1; ZFAS1, ZNFX1 antisense RNA 1.

###### 

HR with 95% CI of lncRNA expression in GC

  lncRNA           Number of articles   Included articles   HR     95% CI       Figure   *P*-value   Heterogeneity (Higgins *I*^2^ statistic)   Total patients
  ---------------- -------------------- ------------------- ------ ------------ -------- ----------- ------------------------------------------ ----------------
  High AFAP1-AS1   2                    3, 4                2.47   1.41--4.30   2        \<0.01      *I*^2^=32.7%, *P*=0.22                     178
  High ANRIL       2                    9, 10               1.68   1.16--2.43   2        \<0.01      *I*^2^=0.0%, *P*=0.84                      220
  High CASC15      2                    18, 19              1.99   1.21--3.28   2        \<0.01      *I*^2^=0.0%, *P*=0.54                      148
  High CCAT2       2                    21, 22              2.17   1.53--3.09   2        \<0.01      *I*^2^=0.0%, *P*=0.76                      193
  High GAPLINC     2                    32, 33              1.49   1.18--1.89   2        \<0.01      *I*^2^=0.0%, *P*=0.76                      123
  High H19         4                    29, 36--38          1.51   1.05--2.17   2        0.03        *I*^2^=64.1%, *P*=0.04                     643
  High HOTAIR      9                    41--49              1.93   1.53--2.43   3        \<0.01      *I*^2^=14.0%, *P*=0.31                     794
  High HOTTIP      3                    50--52              1.57   1.20--2.05   6        \<0.01      *I*^2^=0.2%, *P*=0.37                      540
  High LINC00673   2                    61, 62              2.47   1.45--4.20   6        \<0.01      *I*^2^=0.0%, *P*=0.89                      152
  High MALAT1      4                    43, 72--74          1.70   1.33--2.18   6        \<0.01      *I*^2^=29.7%, *P*=0.23                     496
  Low MEG3         2                    76, 77              1.96   1.17--3.28   6        0.01        *I*^2^=0.0%, *P*=0.95                      206
  High PANDAR      2                    86, 87              3.11   2.72--3.55   6        \<0.01      *I*^2^=0.0%, *P*=0.79                      246
  High PVT1        2                    89, 90              2.17   1.31--3.60   6        \<0.01      *I*^2^=0.0%, *P*=0.87                      191
  High Sox2ot      2                    96, 97              2.30   1.52--3.46   7        \<0.01      *I*^2^=0.0%, *P*=0.35                      287
  Low SPRY4-IT1    2                    98, 99              1.42   0.48--4.22   7        0.53        *I*^2^=71.4%, *P*=0.06                     236
  High UCA1        4                    101--104            1.73   1.12--2.68   7        0.01        *I*^2^=45.5%, *P*=0.14                     399
  High XIST        2                    107, 108            1.89   1.38--2.59   7        \<0.01      *I*^2^=23.4%, *P*=0.25                     204
  High ZEB1-AS1    2                    109, 110            2.07   1.67--2.56   7        \<0.01      *I*^2^=0.0%, *P*=0.62                      831
  High ZFAS1       2                    111, 112            2.51   1.34--4.69   7        \<0.01      *I*^2^=0.0%, *P*=0.93                      158

**Abbreviations:** AFAP1-AS1, AFAP1 antisense RNA 1; ANRIL, CDKN2B antisense RNA 1; CASC15, cancer susceptibility 15; CCAT2, colon cancer associated transcript 2; GAPLINC, gastric adenocarcinoma associated, positive CD44 regulator, long intergenic noncoding RNA; GC, gastric cancer; H19, H19, imprinted maternally expressed transcript; HOTAIR, HOX transcript antisense RNA; HOTTIP, HOXA distal transcript antisense RNA; LINC00673, long intergenic non-protein coding RNA 673; lncRNA, long noncoding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed 3; PANDAR, promoter of CDKN1A antisense DNA damage activated RNA; PVT1, Pvt1 oncogene; Sox2ot, SOX2 overlapping transcript; SPRY4-IT1, SPRY4 intronic transcript 1; UCA1, urothelial cancer associated 1; XIST, X inactive specific transcript; ZEB1-AS1, ZEB1 antisense RNA 1; ZFAS1, ZNFX1 antisense RNA 1.
